ASN Kidney Week 2023
ASN Kidney Week 2023
Advertisement
Victoria SochaHyperkalemia | February 5, 2024
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Read More
Victoria SochaADPKD | February 5, 2024
Results of a study evaluating the prevalence of common comorbid conditions in patients with ADPKD.
Victoria SochaADPKD | February 5, 2024
Clinical development models for polycystic kidney disease remain challenging.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Early diagnosis of CKD and active management can slow progression and improve outcomes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Using antihypertensive medication in patients with persistent treatment-resistant hypertension concurrent with CKD.
Victoria SochaAnemia and Kidney Disease | February 5, 2024
Patients receiving maintenance hemodialysis who develop anemia are commonly treated with erythropoiesis-stimulating agents.
Victoria SochaAnemia and Kidney Disease | February 5, 2024
Patients with end-stage kidney disease with anemia are commonly treated with recombinant human erythropoietin.
Victoria SochaHyperkalemia | February 5, 2024
Examining whether administration of patiromer would reduce the number of significant arrhythmia events.
Victoria SochaHyperkalemia | February 5, 2024
Training an artificial intelligence algorithm that can detect hyperkalemia from the surface electrocardiogram.
Victoria SochaCOVID-19 and Kidney Disease | February 5, 2024
The pooled proportion of all serious adverse effects related to remdesivir was 2.9%.
Victoria SochaCOVID-19 and Kidney Disease | February 5, 2024
Results of an analysis to characterize the sequelae of COVID-19 infection among kidney transplant recipients.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Patients with type 2 diabetes without other comorbidity are often treated with metformin as antiglycemic therapy.
Victoria SochaAnemia and Kidney Disease | February 5, 2024
There are associations between anemia in ESKD and increased risk of morbidity and mortality.
Victoria SochaAnemia and Kidney Disease | February 5, 2024
Interpatient variation in mean hemoglobin levels were smaller in the intervention arm than in the standard of care arm.
Victoria SochaHyperkalemia | February 5, 2024
There is an independent association between hyperkalemia and poor outcomes among individuals with chronic kidney disease.
Victoria SochaHyperkalemia | February 5, 2024
Guideline recommendations call for maintenance of RAASi therapy using novel antihyperkalemia treatment.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Long-term among patients identifying as Black who were treated with voclosporin during the phase 3 AURORA studies.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Tolvaptan showed real-world effectiveness in slowing decline in eGFR when compared with matched historical controls.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Patients with end-stage kidney disease (ESKD) receiving dialysis commonly develop hyperphosphatemia.
Advertisement
Advertisement
Advertisement
Latest News

February 28, 2024